Review
Accepted on 22 Jul 2025
CHEMOTERAPEUTIC NANOPARTICLES FOR GLIOBLASTOMA
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1641752
Type at least 3 characters
1,079 articles
Editorial
Published on 17 Jul 2025
Editorial: Safety consideration in the development of anti-tumor monoclonal antibodies during drug development
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1640377
- 385 views
Original Research
Published on 17 Jul 2025
Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1621045
- 338 views
Systematic Review
Published on 17 Jul 2025
A bibliometric and visual analysis of Jak1 to explore trends and frontiers
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1537508
- 287 views
Original Research
Published on 16 Jul 2025
Utilization of dexrazoxane in patients treated with doxorubicin: a retrospective, propensity matched analysis of cardiac function and toxicity
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1621409
- 386 views
Review
Published on 16 Jul 2025
M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1622359
- 363 views
Review
Accepted on 14 Jul 2025
cGAS-STING signal status after EGFR-TKIs resistance in Non-Small Cell Lung Cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1643349
- 244 views
Original Research
Accepted on 14 Jul 2025
Microvascular endothelial cells PD-L1 expression predicts the efficacy and side effects of anlotinib
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1544278
- 217 views
Original Research
Accepted on 14 Jul 2025
Integrating Network Pharmacology and Transcriptomics to Identify Solasonine's Anti-Osteosarcoma Targets and Experimental Validation
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1614058
Original Research
Published on 11 Jul 2025
AMPs inhibit the proliferation, migration, and invasion of lung cancer via the CHRM3/PI3K/AKT and CHRM3/MAPK pathways
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1582040
- 459 views
Review
Accepted on 08 Jul 2025
Synergistic Strategies in Photodynamic Combination Therapy for Cancer: Mechanisms, Nanotechnology, and Clinical Translation
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1607259
Original Research
Published on 08 Jul 2025
Cell-in-cell associated lncRNA signature predicts prognosis and immunotherapy response in gastric cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1597187
- 423 views
Original Research
Published on 18 Jun 2025
The anti-inflammatory effects of oridonin in resisting esophageal cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1585057
- 950 views
Review
Published on 18 Jun 2025
Aberrant angiogenic signaling in HCC: therapeutic targeting and drug resistance
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1595195
- 912 views
Original Research
Published on 12 Jun 2025
Synergistic effects of 5-fluorouracil in combination with salinomycin promoted ferroptosis via inhibiting SLC7A11/GPX4 in colorectal cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1558290
- 1,122 views
Clinical Trial
Published on 10 Jun 2025
Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1577468
- 1,235 views